Huadong Medicine Co Ltd
SZSE:000963

Watchlist Manager
Huadong Medicine Co Ltd Logo
Huadong Medicine Co Ltd
SZSE:000963
Watchlist
Price: 37.27 CNY 0.32%
Market Cap: 65.4B CNY
Have any thoughts about
Huadong Medicine Co Ltd?
Write Note

Gross Margin
Huadong Medicine Co Ltd

32.3%
Current
31%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
32.3%
=
Gross Profit
13.5B
/
Revenue
41.7B

Gross Margin Across Competitors

Country CN
Market Cap 65.2B CNY
Gross Margin
32%
Country US
Market Cap 77.7B USD
Gross Margin
4%
Country US
Market Cap 48.6B USD
Gross Margin
3%
Country US
Market Cap 48.4B USD
Gross Margin
3%
Country US
Market Cap 30.3B USD
Gross Margin
3%
Country US
Market Cap 9.3B USD
Gross Margin
32%
Country KR
Market Cap 12.2T KRW
Gross Margin
30%
Country CN
Market Cap 64.3B HKD
Gross Margin
8%
Country CN
Market Cap 60.5B CNY
Gross Margin
11%
Country IT
Market Cap 5.5B EUR
Gross Margin
24%
Country DE
Market Cap 5B EUR
Gross Margin
10%
No Stocks Found

Huadong Medicine Co Ltd
Glance View

Market Cap
65.2B CNY
Industry
Health Care

Huadong Medicine Co., Ltd., established in 1995, has emerged as a pivotal player within China's rapidly evolving pharmaceutical landscape. With a robust portfolio that includes innovative cancer treatments, cardiovascular drugs, and biologics, the company focuses on both research and development and the commercialization of high-quality therapeutics. Backed by cutting-edge production facilities and a strong commitment to adhering to international regulatory standards, Huadong not only serves the domestic market but also aspires to extend its reach globally. As the demand for effective healthcare solutions grows, Huadong's strategic alliances and collaborations with research institutions highlight its dedication to staying at the forefront of medical advancements. For investors, Huadong Medicine represents a well-rounded opportunity fueled by a consistent growth trajectory and a commitment to expanding its market presence. The company's focus on high-margin specialty drugs and biologics positions it favorably within the competitive landscape, catering to the increasing prevalence of chronic diseases. With a stable revenue generation model, strong management team, and innovative pipeline, Huadong Medicine is uniquely poised to capture market share and enhance shareholder value in an industry that is increasingly driven by innovation and patient-centric solutions. Investors looking to diversify into the healthcare sector, especially within the growing Asian market, may find Huadong Medicine an attractive addition to their portfolios.

Intrinsic Value
51.07 CNY
Undervaluation 27%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
32.3%
=
Gross Profit
13.5B
/
Revenue
41.7B
What is the Gross Margin of Huadong Medicine Co Ltd?

Based on Huadong Medicine Co Ltd's most recent financial statements, the company has Gross Margin of 32.3%.